A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
Epilepsy, Seizures, Epilepsies, Partial
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring Epilepsy, seizures, new-onset epilepsy, epilepsy relapse, epilepsy monotherapy
Eligibility Criteria
Inclusion Criteria: Patients having new-onset epilepsy or epilepsy relapse characterized by partial-onset seizures or primary generalized tonic-clonic seizures having at least 1 seizure within the 3 months prior to entry who are previously untreated for epilepsy, previously treated for epilepsy, or if currently taking epilepsy medication, must have been taking it for less than 6 weeks weighing at least 25 kilograms (approximately 55 pounds) if female of childbearing potential, must be using an acceptable method of birth control Exclusion Criteria: Patients who have previously taken topiramate for the treatment of epilepsy who are currently taking topiramate for any reason having active liver disease having a clinically significant medical condition or disease women who are pregnant or breastfeeding